Although limitations include the small number of patients with relatively short follow-up time, our results provide the first evidence that RBBP6 could be used as a novel biomarker for improved outcome after colectomy in patients with colon cancer. The gene discussed is RBBP6; the disease is malignant colon neoplasm.